2020 |
Eggers, Maren; Benzinger, Carolin; Suchomel, Miranda; Hjorth, Elmar Future microbiology, 2020. @article{Eggers.2020c, title = {Virucidal activity of three ethanol-based handrubs against murine norovirus in a hand hygiene clinical simulation study}, author = {Maren Eggers and Carolin Benzinger and Miranda Suchomel and Elmar Hjorth}, doi = {10.2217/fmb-2020-0168}, year = {2020}, date = {2020-01-01}, journal = {Future microbiology}, abstract = {Aim: We evaluated the efficacy of three ethanol-based handrubs against murine norovirus~in a proposed clinical simulation test (prEN 17430). Materials & methods: Virucidal activity was determined in 18 volunteers using three~handrubs: ethanol 72.4~and 89.5% v/v solutions, and 86% v/v gel. Subjects underwent testing with each product (3/6~ml~for 15/30~s) and a reference solution (6~ml~70% v/v ethanol for 60~s). Results: Against murine norovirus, the reduction factors~(RF;~RF mean~$pm$ standard deviation~log10 reduction of postsampling) for ethanol gel 86% v/v (RF 1.96~$pm$~0.64), ethanol 89.5% v/v (RF 2.49~$pm$~0.59)~and ethanol 72.4% v/v (RF 2.61~$pm$~0.50), were all significantly superior to that of~the reference solution. Conclusion: All three handrubs passed the criteria set out in prEN 17430 and exhibited excellent virucidal efficacy.}, keywords = {}, pubstate = {published}, tppubtype = {article} } Aim: We evaluated the efficacy of three ethanol-based handrubs against murine norovirus~in a proposed clinical simulation test (prEN 17430). Materials & methods: Virucidal activity was determined in 18 volunteers using three~handrubs: ethanol 72.4~and 89.5% v/v solutions, and 86% v/v gel. Subjects underwent testing with each product (3/6~ml~for 15/30~s) and a reference solution (6~ml~70% v/v ethanol for 60~s). Results: Against murine norovirus, the reduction factors~(RF;~RF mean~$pm$ standard deviation~log10 reduction of postsampling) for ethanol gel 86% v/v (RF 1.96~$pm$~0.64), ethanol 89.5% v/v (RF 2.49~$pm$~0.59)~and ethanol 72.4% v/v (RF 2.61~$pm$~0.50), were all significantly superior to that of~the reference solution. Conclusion: All three handrubs passed the criteria set out in prEN 17430 and exhibited excellent virucidal efficacy. |
Stenger, T; Ledo, A; Ziller, C; Schub, D; Schmidt, T; Enders, M; Gärtner, BC; Sester, M; Meyer, T Timing of Vaccination after Training: Immune Response and Side Effects in Athletes Artikel Medicine and science in sports and exercise, 52 (7), S. 1603–1609, 2020. @article{Stenger.2020, title = {Timing of Vaccination after Training: Immune Response and Side Effects in Athletes}, author = {T Stenger and A Ledo and C Ziller and D Schub and T Schmidt and M Enders and BC G\"{a}rtner and M Sester and T Meyer}, doi = {10.1249/MSS.0000000000002278}, year = {2020}, date = {2020-01-01}, journal = {Medicine and science in sports and exercise}, volume = {52}, number = {7}, pages = {1603--1609}, abstract = {OBJECTIVES Influenza vaccination was used to assess whether induction of immunity or side effects are influenced by the timing of the last training session before vaccination. METHODS Forty-five healthy athletes (36 male, 23 $pm$ 8 yr, $geq$5 training sessions per week, predominantly national competition level) were vaccinated with the tetravalent influenza vaccine; blood samples were collected immediately before and 1, 2, and 26 wk after vaccination. Athletes were randomly assigned to vaccination within 2 h after the last training session versus after 24-26 h. Influenza-specific T cells were quantified after stimulation with the vaccine based on intracellular cytokine staining. Antibodies (IgA, IgG, IgM) were quantified by enzyme-linked immunosorbent assay and neutralization assay. Participants documented resulting side effects and training restrictions using a standardized diary. RESULTS Both groups showed an increase in influenza-reactive CD4 T-cell levels, which peaked 1 wk after vaccination (fold changes to baseline; median (interquartile range), 3.7 (3.0-5.4; P textless 0.001) in the 2-h group; 4.6 (2.8-7.4; P textless 0.001) in the 26-h group) with no difference between groups (P = 0.52). Influenza-specific antibodies showed a significant increase after vaccination in both groups (at least 1.4-fold, each P textless 0.001, no group differences; P = 0.24-0.97 for different antibody types). Only antibodies toward the Brisbane strain showed a trend toward significant differences in neutralization titers between groups (4-fold (2-17.8) in the 2-h group, 16-fold (4-32.9) in the 26-h group; P = 0.06), whereas other specificities did not differ (P = 0.16-0.72). No intergroup differences were found for side effects; no athlete reported a loss of training time due to the vaccination or its side effects. CONCLUSION Infection prophylaxis in elite athletes by influenza vaccination seems to be effective and safe. Timing of vaccination after prior training does not seem to require specific constraints.}, keywords = {}, pubstate = {published}, tppubtype = {article} } OBJECTIVES Influenza vaccination was used to assess whether induction of immunity or side effects are influenced by the timing of the last training session before vaccination. METHODS Forty-five healthy athletes (36 male, 23 $pm$ 8 yr, $geq$5 training sessions per week, predominantly national competition level) were vaccinated with the tetravalent influenza vaccine; blood samples were collected immediately before and 1, 2, and 26 wk after vaccination. Athletes were randomly assigned to vaccination within 2 h after the last training session versus after 24-26 h. Influenza-specific T cells were quantified after stimulation with the vaccine based on intracellular cytokine staining. Antibodies (IgA, IgG, IgM) were quantified by enzyme-linked immunosorbent assay and neutralization assay. Participants documented resulting side effects and training restrictions using a standardized diary. RESULTS Both groups showed an increase in influenza-reactive CD4 T-cell levels, which peaked 1 wk after vaccination (fold changes to baseline; median (interquartile range), 3.7 (3.0-5.4; P textless 0.001) in the 2-h group; 4.6 (2.8-7.4; P textless 0.001) in the 26-h group) with no difference between groups (P = 0.52). Influenza-specific antibodies showed a significant increase after vaccination in both groups (at least 1.4-fold, each P textless 0.001, no group differences; P = 0.24-0.97 for different antibody types). Only antibodies toward the Brisbane strain showed a trend toward significant differences in neutralization titers between groups (4-fold (2-17.8) in the 2-h group, 16-fold (4-32.9) in the 26-h group; P = 0.06), whereas other specificities did not differ (P = 0.16-0.72). No intergroup differences were found for side effects; no athlete reported a loss of training time due to the vaccination or its side effects. CONCLUSION Infection prophylaxis in elite athletes by influenza vaccination seems to be effective and safe. Timing of vaccination after prior training does not seem to require specific constraints. |
Russcher, A; Enders, A; de Brouwer, CS; Oepkes, D; Hahn, R; Enders, M; Kroes, AC M; Vossen, CTM A Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 129 , S. 104482, 2020. @article{Russcher.2020, title = {Diagnosis of intrauterine parvovirus B19 infection at birth - Value of DNA detection in neonatal blood and dried blood spots}, author = {A Russcher and A Enders and CS de Brouwer and D Oepkes and R Hahn and M Enders and AC M Kroes and A CTM Vossen}, doi = {10.1016/j.jcv.2020.104482}, year = {2020}, date = {2020-01-01}, journal = {Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology}, volume = {129}, pages = {104482}, abstract = {BACKGROUND Diagnosis of congenital viral infection at birth is generally attempted by direct detection of the virus by PCR in various neonatal materials. How to reliably diagnose intrauterine infection with parvovirus B19 (B19 V) at birth is unknown. OBJECTIVES To evaluate the performance of B19 V DNA detection in cord blood (CB) or neonatal dried blood spots (DBS) in diagnosing fetal infection. STUDY DESIGN Two cohorts of children diagnosed prenatally with an intrauterine B19 V infection were included in this study. CB samples of intrauterine B19 V infections that were sent to a reference laboratory for congenital infections in Stuttgart, Germany in the period 1995-2014 were tested in triplicate for B19 V DNA by quantitative PCR. DBS from children with intrauterine B19 V infection that underwent IUT at the LUMC, Leiden, the Netherlands in the period 2009-2014 were tested for B19 V DNA by quantitative B19 V PCR in triplicate. RESULTS Fourteen of twenty (70 %) CB samples tested positive for B19 V DNA. The positivity rate was 40 % (4/10) in those with a prenatal diagnosis textless20 weeks gestation. When intrauterine B19 V infection was diagnosed thereafter, 100 % (10/10) samples were B19 V DNA positive. Of the thirteen available DBS, twelve (92 %) tested positive. Viral load in CB and DBS corresponded inversely with time from fetal diagnosis to birth. CONCLUSION B19 V DNA can be detected in neonatal blood samples of children following intrauterine B19 V infection, although the possibility of false-negatives, even in severe infections, should be considered. B19 V viral load at birth correlates with timing of infection.}, keywords = {}, pubstate = {published}, tppubtype = {article} } BACKGROUND Diagnosis of congenital viral infection at birth is generally attempted by direct detection of the virus by PCR in various neonatal materials. How to reliably diagnose intrauterine infection with parvovirus B19 (B19 V) at birth is unknown. OBJECTIVES To evaluate the performance of B19 V DNA detection in cord blood (CB) or neonatal dried blood spots (DBS) in diagnosing fetal infection. STUDY DESIGN Two cohorts of children diagnosed prenatally with an intrauterine B19 V infection were included in this study. CB samples of intrauterine B19 V infections that were sent to a reference laboratory for congenital infections in Stuttgart, Germany in the period 1995-2014 were tested in triplicate for B19 V DNA by quantitative PCR. DBS from children with intrauterine B19 V infection that underwent IUT at the LUMC, Leiden, the Netherlands in the period 2009-2014 were tested for B19 V DNA by quantitative B19 V PCR in triplicate. RESULTS Fourteen of twenty (70 %) CB samples tested positive for B19 V DNA. The positivity rate was 40 % (4/10) in those with a prenatal diagnosis textless20 weeks gestation. When intrauterine B19 V infection was diagnosed thereafter, 100 % (10/10) samples were B19 V DNA positive. Of the thirteen available DBS, twelve (92 %) tested positive. Viral load in CB and DBS corresponded inversely with time from fetal diagnosis to birth. CONCLUSION B19 V DNA can be detected in neonatal blood samples of children following intrauterine B19 V infection, although the possibility of false-negatives, even in severe infections, should be considered. B19 V viral load at birth correlates with timing of infection. |
Rabenau, HF; Schwebke, I; Blümel, J; Eggers, M; Rapp, I; Steinmann, J; Willkommen, H Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 63 (5), S. 657–659, 2020, ISSN: 1436-9990. @article{Rabenau.2020b, title = {Comment on the significance, application and determination of the large volume plating (LVP) 2. Communication of the DVV/GfV Virus Disinfection Expert Committee on the DVV/RKI Guideline in the version of December 1st, 2014}, author = {HF Rabenau and I Schwebke and J Bl\"{u}mel and M Eggers and I Rapp and J Steinmann and H Willkommen}, doi = {10.1007/s00103-020-03117-8}, issn = {1436-9990}, year = {2020}, date = {2020-01-01}, journal = {Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz}, volume = {63}, number = {5}, pages = {657--659}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Meier, T; Enders, M High reproducibility of the interferon-gamma release assay T-SPOT.TB in serial testing Artikel European journal of clinical microbiology & infectious diseases, 2020, ISSN: 0934-9723. @article{Meier.2020, title = {High reproducibility of the interferon-gamma release assay T-SPOT.TB in serial testing}, author = {T Meier and M Enders}, doi = {10.1007/s10096-020-03997-3}, issn = {0934-9723}, year = {2020}, date = {2020-01-01}, journal = {European journal of clinical microbiology & infectious diseases}, abstract = {Longitudinal studies regarding the reproducibility of Interferon-gamma release assay (IGRA) T-SPOT.TB for the diagnosis of Mycobacterium tuberculosis (M. tb) infection in serial testing are limited. We retrospectively analysed results of serially tested subjects in a medical laboratory in Germany over a time period of 14~years. From October 2004 to December 2018, a total of 5440 subjects were identified with a second T-SPOT.TB test after a median time interval of 258~days (interquartile range [IQR] 62-665). Consistently negative (n = 4520) or positive results (n = 682) were observed in 5202 (95.6%) subjects, indicating a high degree of concordance in serial testing (textgreekk = 0.83). Test conversions occurred in 101 of 4621 (2.2%) subjects with initially negative tests. Of 819 subjects with initially positive test results, 137 (16.7%) had a test reversion which was associated with low spot numbers of the first test. Of 529 subjects retested within 1~year, only 60 (11.3%) displayed a test reversion. In subjects retested after more than 1~year, 77 of 290 (26.6%) tests reverted. This significantly higher rate of test reversions after more than 1~year was age-dependent and only observed in subjects above the age of 40~years. In the medical laboratory, the T-SPOT.TB test demonstrates a high reproducibility in serial testing.}, keywords = {}, pubstate = {published}, tppubtype = {article} } Longitudinal studies regarding the reproducibility of Interferon-gamma release assay (IGRA) T-SPOT.TB for the diagnosis of Mycobacterium tuberculosis (M. tb) infection in serial testing are limited. We retrospectively analysed results of serially tested subjects in a medical laboratory in Germany over a time period of 14~years. From October 2004 to December 2018, a total of 5440 subjects were identified with a second T-SPOT.TB test after a median time interval of 258~days (interquartile range [IQR] 62-665). Consistently negative (n = 4520) or positive results (n = 682) were observed in 5202 (95.6%) subjects, indicating a high degree of concordance in serial testing (textgreekk = 0.83). Test conversions occurred in 101 of 4621 (2.2%) subjects with initially negative tests. Of 819 subjects with initially positive test results, 137 (16.7%) had a test reversion which was associated with low spot numbers of the first test. Of 529 subjects retested within 1~year, only 60 (11.3%) displayed a test reversion. In subjects retested after more than 1~year, 77 of 290 (26.6%) tests reverted. This significantly higher rate of test reversions after more than 1~year was age-dependent and only observed in subjects above the age of 40~years. In the medical laboratory, the T-SPOT.TB test demonstrates a high reproducibility in serial testing. |
Kramer, A; Eggers, M Prävention respiratorischer Virusinfektionen durch viruzide Schleimhautantiseptik bei medizinischem Personal und in der Bevölkerung Artikel Hygiene + Medizin, 45 (9), S. D118–D124, 2020, ISSN: 0172-3790. @article{Kramer.2020, title = {Pr\"{a}vention respiratorischer Virusinfektionen durch viruzide Schleimhautantiseptik bei medizinischem Personal und in der Bev\"{o}lkerung}, author = {A Kramer and M Eggers}, issn = {0172-3790}, year = {2020}, date = {2020-01-01}, journal = {Hygiene + Medizin}, volume = {45}, number = {9}, pages = {D118\textendashD124}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Elts, B; Rager, A-M; Boursillon, D; Eggers, M Aufbereitung von Reinigungstextilien in der Krankenhausreinigung Artikel Hygiene + Medizin, 45 (7/8), S. D80–D89, 2020, ISSN: 0172-3790. @article{Elts.2020, title = {Aufbereitung von Reinigungstextilien in der Krankenhausreinigung}, author = {B Elts and A-M Rager and D Boursillon and M Eggers}, issn = {0172-3790}, year = {2020}, date = {2020-01-01}, journal = {Hygiene + Medizin}, volume = {45}, number = {7/8}, pages = {D80--D89}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Eggers, M; Rabenau, H; Blümel, J; Fickenscher, H; Geisel, B; Glebe, D; Hengel, H; Marschang, R; Reiche, S; Steinmann, E; Steinmann, J; Schwebke, I Epidemiologisches Bulletin, (36), S. 3–14, 2020. @article{Eggers.2020b, title = {Einsatz geeigneter Desinfektionsmitteln bei gentechnisch ver\"{a}nderten Viren und viralen Vektoren -- Stellungnahme der Kommission f\"{u}r Virusdesinfektion der Deutschen Vereinigung zur Bek\"{a}mpfung der Viruskrankheiten (DVV) e. V. und der Gesellschaft f\"{u}r Virologie (GfV) e. V}, author = {M Eggers and H Rabenau and J Bl\"{u}mel and H Fickenscher and B Geisel and D Glebe and H Hengel and R Marschang and S Reiche and E Steinmann and J Steinmann and I Schwebke}, doi = {10.25646/7030}, year = {2020}, date = {2020-01-01}, journal = {Epidemiologisches Bulletin}, number = {36}, pages = {3--14}, abstract = {Im Epidemiologischen Bulletin 36/2020 haben Mitglieder der Kommission f\"{u}r Virusdesinfektion der DVV/GfV eine \"{U}bersicht h\"{a}ufig verwendeter gentechnisch ver\"{a}nderter Organismen zusammengestellt, davon ausgehend werden Aspekte der Auswahl und Anwendung von Desinfektionsmitteln n\"{a}her er\"{o}rtert. Dabei wurden neben Vertretern von Bundesoberbeh\"{o}rden, wie des FLI, des PEI und des RKI, auch Vertreter des \"{O}GD und virologischer Institute aus Universit\"{a}ten einbezogen.}, keywords = {}, pubstate = {published}, tppubtype = {article} } Im Epidemiologischen Bulletin 36/2020 haben Mitglieder der Kommission für Virusdesinfektion der DVV/GfV eine Übersicht häufig verwendeter gentechnisch veränderter Organismen zusammengestellt, davon ausgehend werden Aspekte der Auswahl und Anwendung von Desinfektionsmitteln näher erörtert. Dabei wurden neben Vertretern von Bundesoberbehörden, wie des FLI, des PEI und des RKI, auch Vertreter des ÖGD und virologischer Institute aus Universitäten einbezogen. |
Eggers, M; Hitz, DA; Elts, B Reinigung von Oberflächen - Eine mikrobiologische Untersuchung und Bewertung der Reinigung in öffentlichen Bereichen Artikel Hygiene + Medizin, 45 (7-8), S. D102–D106, 2020, ISSN: 0172-3790. @article{Eggers.2020, title = {Reinigung von Oberfl\"{a}chen - Eine mikrobiologische Untersuchung und Bewertung der Reinigung in \"{o}ffentlichen Bereichen}, author = {M Eggers and DA Hitz and B Elts}, issn = {0172-3790}, year = {2020}, date = {2020-01-01}, journal = {Hygiene + Medizin}, volume = {45}, number = {7-8}, pages = {D102--D106}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Boursillon, D; Kocics, J; Eggers, M; Elts, B Reiniger mit Zusatz von Mikroorganismen (MARP) Artikel Hygiene + Medizin, 45 (7/8), S. 98–101, 2020, ISSN: 0172-3790. @article{Boursillon.2020, title = {Reiniger mit Zusatz von Mikroorganismen (MARP)}, author = {D Boursillon and J Kocics and M Eggers and B Elts}, issn = {0172-3790}, year = {2020}, date = {2020-01-01}, journal = {Hygiene + Medizin}, volume = {45}, number = {7/8}, pages = {98--101}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Anderson, DE; Sivalingam, V; Kang, Eng Zheng A; Ananthanarayanan, A; Arumugam, H; Jenkins, TM; Hadjiat, Y; Eggers, M Infectious diseases and therapy, 9 (3), S. 669–675, 2020, ISSN: 2193-8229. @article{Anderson.2020, title = {Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease}, author = {DE Anderson and V Sivalingam and A Eng Zheng Kang and A Ananthanarayanan and H Arumugam and TM Jenkins and Y Hadjiat and M Eggers}, doi = {10.1007/s40121-020-00316-3}, issn = {2193-8229}, year = {2020}, date = {2020-01-01}, journal = {Infectious diseases and therapy}, volume = {9}, number = {3}, pages = {669\textendash675}, abstract = {INTRODUCTION As of 22 June 2020, Severe Acute Respiratory Syndrome (SARS)-coronavirus (CoV)-2 has infected more than 8.95 million people worldwide, causing textgreater 468,000 deaths. The virus is transmitted through respiratory droplets and physical contact from contaminated surfaces to the mucosa. Hand hygiene and oral decontamination among other measures are key to preventing the spread of the virus. We report the in vitro virucidal activity of topical and oral povidone-iodine (PVP-I) products against SARS-CoV-2. METHODS Suspension assays were used to assess the virucidal activity of PVP-I against SARS-CoV-2. Products were tested at a contact time of 30~s for virucidal activity. Viral titres were calculated using the Spearman-K\"{a}rber method and reported as median tissue culture infectious dose (TCID50)/mL. RESULTS All four products [antiseptic solution (PVP-I 10%), skin cleanser (PVP-I 7.5%), gargle and mouth wash (PVP-I 1%) and throat spray (PVP-I 0.45%)] achieved $geq$ 99.99% virucidal activity against SARS-CoV-2, corresponding to $geq$ 4 log10 reduction of virus titre, within 30~s of contact. CONCLUSION This study provides evidence of rapid and effective virucidal activity of PVP-I against SARS-CoV-2. PVP-I-based products are widely available for medical and personal use for hand hygiene and oral decontamination, and could be readily integrated into coronavirus disease, COVID-19, infection control measures in hospital and community settings.}, keywords = {}, pubstate = {published}, tppubtype = {article} } INTRODUCTION As of 22 June 2020, Severe Acute Respiratory Syndrome (SARS)-coronavirus (CoV)-2 has infected more than 8.95 million people worldwide, causing textgreater 468,000 deaths. The virus is transmitted through respiratory droplets and physical contact from contaminated surfaces to the mucosa. Hand hygiene and oral decontamination among other measures are key to preventing the spread of the virus. We report the in vitro virucidal activity of topical and oral povidone-iodine (PVP-I) products against SARS-CoV-2. METHODS Suspension assays were used to assess the virucidal activity of PVP-I against SARS-CoV-2. Products were tested at a contact time of 30~s for virucidal activity. Viral titres were calculated using the Spearman-Kärber method and reported as median tissue culture infectious dose (TCID50)/mL. RESULTS All four products [antiseptic solution (PVP-I 10%), skin cleanser (PVP-I 7.5%), gargle and mouth wash (PVP-I 1%) and throat spray (PVP-I 0.45%)] achieved $geq$ 99.99% virucidal activity against SARS-CoV-2, corresponding to $geq$ 4 log10 reduction of virus titre, within 30~s of contact. CONCLUSION This study provides evidence of rapid and effective virucidal activity of PVP-I against SARS-CoV-2. PVP-I-based products are widely available for medical and personal use for hand hygiene and oral decontamination, and could be readily integrated into coronavirus disease, COVID-19, infection control measures in hospital and community settings. |
Munz, M; Wessendorf, S; Koretsis, G; Tewald, F; Baegi, R; Krämer, S; Geissler, M; Reinhard, M Acute transverse myelitis after COVID-19 pneumonia Artikel Journal of neurology, 267 , S. 2196-2197, 2020, ISSN: 0340-5354. @article{Munz.2020, title = {Acute transverse myelitis after COVID-19 pneumonia}, author = {M Munz and S Wessendorf and G Koretsis and F Tewald and R Baegi and S Kr\"{a}mer and M Geissler and M Reinhard}, doi = {10.1007/s00415-020-09934-w}, issn = {0340-5354}, year = {2020}, date = {2020-01-01}, journal = {Journal of neurology}, volume = {267}, pages = {2196-2197}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Hitz, DA; Tewald, F; Eggers, M Seasonal Bordetella pertussis pattern in the period from 2008 to 2018 in Germany Artikel BMC infectious diseases, 20 (1), S. 474, 2020, ISSN: 1471-2334. @article{Hitz.2020b, title = {Seasonal Bordetella pertussis pattern in the period from 2008 to 2018 in Germany}, author = {DA Hitz and F Tewald and M Eggers}, doi = {10.1186/s12879-020-05199-w}, issn = {1471-2334}, year = {2020}, date = {2020-01-01}, journal = {BMC infectious diseases}, volume = {20}, number = {1}, pages = {474}, abstract = {BACKGROUND After the introduction of a vaccine against B. pertussis the seasonal pattern with the highest number of infections in the spring to summer months changed. Recent studies from around the world suggest that B. pertussis infections again follow a seasonal pattern with increased incidence in summer.The aim of this study was to investigate whether respiratory infections caused by B. pertussis in the period from January 2008 to December 2018 also seasonally spread in Germany and if so, when the B. pertussis activity peaked. METHODS We tested 19,031 samples, mainly from Southern Germany, collected in the period from January 2008 to December 2018 using a Multiplex PCR assay. We assessed the number and proportion of samples positive for B. pertussis, stratified by patient's age and month. The seasonal distribution was investigated by plotting the average proportion of positive samples for each month. RESULTS We observed a B. pertussis seasonality with the highest number of positive samples in the months from June until September. In contrast, testing of samples for B. pertussis was requested most frequently in the period from October until March. The proportion of positive samples increased earlier in adolescents (age 10 to 19) than in other age groups. CONCLUSIONS We found a seasonality of B. pertussis infections in Germany, which differs from the time when most samples are sent in for testing of B. pertussis. Our study suggests that clinicians should be more aware of B. pertussis infections in the months from June until September to prevent further transmission to vulnerable family members.}, keywords = {}, pubstate = {published}, tppubtype = {article} } BACKGROUND After the introduction of a vaccine against B. pertussis the seasonal pattern with the highest number of infections in the spring to summer months changed. Recent studies from around the world suggest that B. pertussis infections again follow a seasonal pattern with increased incidence in summer.The aim of this study was to investigate whether respiratory infections caused by B. pertussis in the period from January 2008 to December 2018 also seasonally spread in Germany and if so, when the B. pertussis activity peaked. METHODS We tested 19,031 samples, mainly from Southern Germany, collected in the period from January 2008 to December 2018 using a Multiplex PCR assay. We assessed the number and proportion of samples positive for B. pertussis, stratified by patient's age and month. The seasonal distribution was investigated by plotting the average proportion of positive samples for each month. RESULTS We observed a B. pertussis seasonality with the highest number of positive samples in the months from June until September. In contrast, testing of samples for B. pertussis was requested most frequently in the period from October until March. The proportion of positive samples increased earlier in adolescents (age 10 to 19) than in other age groups. CONCLUSIONS We found a seasonality of B. pertussis infections in Germany, which differs from the time when most samples are sent in for testing of B. pertussis. Our study suggests that clinicians should be more aware of B. pertussis infections in the months from June until September to prevent further transmission to vulnerable family members. |
Hübner, N-O; Eggers, M; Schwebke, I; Suchomel, M Händedesinfektion unter den Bedingungen der SARSCoV- 2-Pandemie Artikel Epidemiologisches Bulletin, 19 , S. 13-19, 2020. @article{Hubner.2020, title = {H\"{a}ndedesinfektion unter den Bedingungen der SARSCoV- 2-Pandemie}, author = {N-O H\"{u}bner and M Eggers and I Schwebke and M Suchomel}, url = {https://edoc.rki.de/handle/176904/6774?show=full}, doi = {10.25646/6861}, year = {2020}, date = {2020-01-01}, journal = {Epidemiologisches Bulletin}, volume = {19}, pages = {13-19}, abstract = {Die aktuelle SARS-CoV-2-Pandemie f\"{u}hrt uns zum einen den Stellenwert der H\"{a}ndedesinfektion zum Schutz der Patienten und Besch\"{a}ftigten vor Augen. Zum anderen zeigt sie, wie wichtig die stete Verf\"{u}gbarkeit von H\"{a}ndedesinfektionsmitteln ist, deren Wirksamkeit, Qualit\"{a}t und Unbedenklichkeit nachgewiesen und die unter praktischen Bedingungen tauglich sind. Aussagen u. a. zu Bestandteilen, zur Deklaration der Wirksamkeit und zur Qualit\"{a}t von alkoholischen H\"{a}ndedesinfektionsmitteln werden im Epidemiologischen Bulletin 19/2020 n\"{a}her ausgef\"{u}hrt.}, keywords = {}, pubstate = {published}, tppubtype = {article} } Die aktuelle SARS-CoV-2-Pandemie führt uns zum einen den Stellenwert der Händedesinfektion zum Schutz der Patienten und Beschäftigten vor Augen. Zum anderen zeigt sie, wie wichtig die stete Verfügbarkeit von Händedesinfektionsmitteln ist, deren Wirksamkeit, Qualität und Unbedenklichkeit nachgewiesen und die unter praktischen Bedingungen tauglich sind. Aussagen u. a. zu Bestandteilen, zur Deklaration der Wirksamkeit und zur Qualität von alkoholischen Händedesinfektionsmitteln werden im Epidemiologischen Bulletin 19/2020 näher ausgeführt. |
Hitz, D; Exler, S; Daiminger, A; Bartelt, U; Enders, M Low-level positive results in the Liaison CMV IgG II assay may misclassify pregnant woman as immune Artikel Diagnostic microbiology and infectious disease, S. 115029, 2020. @article{Hitz.2020, title = {Low-level positive results in the Liaison CMV IgG II assay may misclassify pregnant woman as immune}, author = {D Hitz and S Exler and A Daiminger and U Bartelt and M Enders}, doi = {10.1016/j.diagmicrobio.2020.115029}, year = {2020}, date = {2020-01-01}, journal = {Diagnostic microbiology and infectious disease}, pages = {115029}, abstract = {The aim of this study is to report on the specificity in the low-positive range of the Liaison CMV IgG II assay for determination of cytomegalovirus immune status in pregnancy. Sera with test results between 12.0 and 40.0 U/mL were retested with the Enzygnost Anti-CMV/IgG assay. Enzygnost-negative samples were analyzed by the Serion ELISA classic Cytomegalovirus IgG assay and, if positive or equivocal, also with the Mikrogen recomLine CMV IgG assay. A total of 12,117 sera were tested with the Liaison assay. Sixty sera were equivocal (12.0-13.9 U/mL), and 400 of 4295 positive sera were low-positive (14.0-40.0 U/mL). Based on consensus, at least 14% of the low-positives and 1.3% of all Liaison-positives can be considered as misclassified. The proportion of misclassified sera increased with lower Liaison IgG results. We suggest that the range for equivocal results in the Liaison assay should be revised.}, keywords = {}, pubstate = {published}, tppubtype = {article} } The aim of this study is to report on the specificity in the low-positive range of the Liaison CMV IgG II assay for determination of cytomegalovirus immune status in pregnancy. Sera with test results between 12.0 and 40.0 U/mL were retested with the Enzygnost Anti-CMV/IgG assay. Enzygnost-negative samples were analyzed by the Serion ELISA classic Cytomegalovirus IgG assay and, if positive or equivocal, also with the Mikrogen recomLine CMV IgG assay. A total of 12,117 sera were tested with the Liaison assay. Sixty sera were equivocal (12.0-13.9 U/mL), and 400 of 4295 positive sera were low-positive (14.0-40.0 U/mL). Based on consensus, at least 14% of the low-positives and 1.3% of all Liaison-positives can be considered as misclassified. The proportion of misclassified sera increased with lower Liaison IgG results. We suggest that the range for equivocal results in the Liaison assay should be revised. |
Rabenau, HF; Schwebke, I; Blümel, J; Eggers, M; Glebe, D; Rapp, I; Sauerbrei, A; Steinmann, E; Steinmann, J; Willkommen, He; Wutzler, P Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 63 (5), S. 645–655, 2020, ISSN: 1436-9990. @article{Rabenau.2020, title = {Guideline for testing chemical disinfectants regarding their virucidal activity within the field of human medicine : as of December 1st, 2014 Prepared by the German Association for the Control of Virus Diseases (DVV) and the Robert Koch Institute (RKI)}, author = {HF Rabenau and I Schwebke and J Bl\"{u}mel and M Eggers and D Glebe and I Rapp and A Sauerbrei and E Steinmann and J Steinmann and He Willkommen and P Wutzler}, doi = {10.1007/s00103-020-03115-w}, issn = {1436-9990}, year = {2020}, date = {2020-01-01}, journal = {Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz}, volume = {63}, number = {5}, pages = {645--655}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Ledo, A; Schub, D; Ziller, C; Enders, M; Stenger, T; Gärtner, BC; Schmidt, T; Meyer, T; Sester, M Brain, behavior, and immunity, 83 , S. 135-145, 2020. @article{Ledo.2020, title = {Elite athletes on regular training show more pronounced induction of vaccine-specific T-cells and antibodies after tetravalent influenza vaccination than controls}, author = {A Ledo and D Schub and C Ziller and M Enders and T Stenger and BC G\"{a}rtner and T Schmidt and T Meyer and M Sester}, doi = {10.1016/j.bbi.2019.09.024}, year = {2020}, date = {2020-01-01}, journal = {Brain, behavior, and immunity}, volume = {83}, pages = {135-145}, abstract = {Compliance of elite athletes with vaccination recommendations is low mainly based on concerns about side-effects and perceived poor vaccine efficacy due to continued physical training. We therefore employed seasonal influenza vaccination to investigate the effect of regular physical training on vaccine-induced cellular and humoral immunity in elite athletes and controls. Lymphocyte subpopulations and vaccine-specific T-cells were quantified and functionally characterized from 45 athletes and 25 controls before, and 1, 2 and 26 weeks after vaccination. Moreover, influenza-specific antibodies and their neutralizing function were quantified. Both groups showed a significant increase in vaccine-reactive CD4 T-cell levels which peaked one week after vaccination (p textless 0.0001). The increase was significantly more pronounced in athletes (4.1-fold) compared to controls (2.3-fold; p = 0.0007). The cytokine profile changed from multifunctional T-cells co-producing IFNtextgreekg, IL-2 and TNFtextgree\k{a} to cells with restricted cytokine expression. This change in functionality was associated with a significant increase in CTLA-4 expression (p textless 0.0001), which again was more pronounced in athletes. Likewise, the increase in neutralizing antibodies was stronger in athletes (p = 0.004 for H1N1; p = 0.032 for H3N2). In conclusion, both groups mounted a strong vaccine-specific cellular and humoral immunity after standard vaccination. The more pronounced increase in specific T-cells and neutralizing antibodies indicates that high frequency and intensity of training enhance vaccine-responses in elite athletes.}, keywords = {}, pubstate = {published}, tppubtype = {article} } Compliance of elite athletes with vaccination recommendations is low mainly based on concerns about side-effects and perceived poor vaccine efficacy due to continued physical training. We therefore employed seasonal influenza vaccination to investigate the effect of regular physical training on vaccine-induced cellular and humoral immunity in elite athletes and controls. Lymphocyte subpopulations and vaccine-specific T-cells were quantified and functionally characterized from 45 athletes and 25 controls before, and 1, 2 and 26 weeks after vaccination. Moreover, influenza-specific antibodies and their neutralizing function were quantified. Both groups showed a significant increase in vaccine-reactive CD4 T-cell levels which peaked one week after vaccination (p textless 0.0001). The increase was significantly more pronounced in athletes (4.1-fold) compared to controls (2.3-fold; p = 0.0007). The cytokine profile changed from multifunctional T-cells co-producing IFNtextgreekg, IL-2 and TNFtextgreeą to cells with restricted cytokine expression. This change in functionality was associated with a significant increase in CTLA-4 expression (p textless 0.0001), which again was more pronounced in athletes. Likewise, the increase in neutralizing antibodies was stronger in athletes (p = 0.004 for H1N1; p = 0.032 for H3N2). In conclusion, both groups mounted a strong vaccine-specific cellular and humoral immunity after standard vaccination. The more pronounced increase in specific T-cells and neutralizing antibodies indicates that high frequency and intensity of training enhance vaccine-responses in elite athletes. |
2019 |
Kohmer, N; Nagel, A; Berger, A; Enders, M; Hamprecht, K; Korn, K; Kortenbusch, M; Überla, K; Rabenau, H F Laboratory diagnosis of congenital CMV infection in newborns: Impact of pre-analytic factors Artikel Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 115 , S. 32–36, 2019, ISSN: 1386-6532. @article{Kohmer.2019, title = {Laboratory diagnosis of congenital CMV infection in newborns: Impact of pre-analytic factors}, author = {N Kohmer and A Nagel and A Berger and M Enders and K Hamprecht and K Korn and M Kortenbusch and K \"{U}berla and H F Rabenau}, doi = {10.1016/j.jcv.2019.03.017}, issn = {1386-6532}, year = {2019}, date = {2019-01-01}, journal = {Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology}, volume = {115}, pages = {32--36}, abstract = {BACKGROUND To identify infants with congenital cytomegalovirus (cCMV) saliva polymerase chain reaction (PCR) is an ideal screening method. However, there are only few data on the influence of pre-analytic factors on the analytical sensitivity of the CMV PCR. OBJECTIVES This study aimed to evaluate the performance of different swabbing materials, transport time and initial virus concentration regarding to the efficacy of recovery of CMV-DNA. STUDY DESIGN Two CMV suspensions containing a high or low concentration of the laboratory strain AD 169 were prepared as test samples. Sampling was simulated by immersion of different swabs in these CMV suspensions and storing the swabs dry or in specified transport media. Transport conditions were modeled by storing the samples for defined time periods prior to DNA extraction and quantitative PCR analyses. Parallel analyses in two different laboratories allowed determination of lab to lab consistency. RESULTS The duration of storage under the conditions analysed did not have a major effect on the recovery efficiency for the swabbing materials tested. With exception of flocked dry swabs, all tested swabbing materials demonstrated good recovery of CMV DNA. The flocked swab/eNAT system showed the best overall performance. CONCLUSIONS All tested swabbing materials (with exception of the flocked dry swabs) seem to be well suited for recovery of CMV DNA and appropriate for use for the diagnosis of cCMV infection in symptomatic cases and in general cCMV screening programs of newborns.}, keywords = {}, pubstate = {published}, tppubtype = {article} } BACKGROUND To identify infants with congenital cytomegalovirus (cCMV) saliva polymerase chain reaction (PCR) is an ideal screening method. However, there are only few data on the influence of pre-analytic factors on the analytical sensitivity of the CMV PCR. OBJECTIVES This study aimed to evaluate the performance of different swabbing materials, transport time and initial virus concentration regarding to the efficacy of recovery of CMV-DNA. STUDY DESIGN Two CMV suspensions containing a high or low concentration of the laboratory strain AD 169 were prepared as test samples. Sampling was simulated by immersion of different swabs in these CMV suspensions and storing the swabs dry or in specified transport media. Transport conditions were modeled by storing the samples for defined time periods prior to DNA extraction and quantitative PCR analyses. Parallel analyses in two different laboratories allowed determination of lab to lab consistency. RESULTS The duration of storage under the conditions analysed did not have a major effect on the recovery efficiency for the swabbing materials tested. With exception of flocked dry swabs, all tested swabbing materials demonstrated good recovery of CMV DNA. The flocked swab/eNAT system showed the best overall performance. CONCLUSIONS All tested swabbing materials (with exception of the flocked dry swabs) seem to be well suited for recovery of CMV DNA and appropriate for use for the diagnosis of cCMV infection in symptomatic cases and in general cCMV screening programs of newborns. |
Kagan, K O; Enders, M; Schampera, M S; Baeumel, E; Hoopmann, M; Geipel, A; Berg, C; Goelz, R; de Catte, L; Wallwiener, D; Brucker, S; Adler, S P; Jahn, G; Hamprecht, K Ultrasound in obstetrics & gynecology, 53 (3), S. 383–389, 2019, ISSN: 0960-7692. @article{Kagan.2019b, title = {Prevention of maternal-fetal transmission of CMV by hyperimmunoglobulin (HIG) administered after a primary maternal CMV infectionin early gestation}, author = {K O Kagan and M Enders and M S Schampera and E Baeumel and M Hoopmann and A Geipel and C Berg and R Goelz and L de Catte and D Wallwiener and S Brucker and S P Adler and G Jahn and K Hamprecht}, doi = {10.1002/uog.19164}, issn = {0960-7692}, year = {2019}, date = {2019-01-01}, journal = {Ultrasound in obstetrics & gynecology}, volume = {53}, number = {3}, pages = {383--389}, abstract = {OBJECTIVE To examine the efficacy of biweekly hyperimmunoglobulin (HIG) administration to women with first trimester CMV infection for preventing maternal-fetal transmission of CMV. METHODS Subjects were 40 pregnant women with a primary CMV infection with a median gestational age at diagnosis of 9.6 weeks with a range of 5.1 to 14.3 weeks' gestation. On average, HIG administration started at 11.1 weeks and continued until 16.6 weeks' gestation. Within this interval, HIG was administered between 2 and 6 times. While CMV IgG monitoring showed periodic fluctuations during biweekly HIG administration cycles, high CMV IgG avidity indices remained stable over the whole treatment period. The results were compared with a historic cohort with first trimester CMV infection without treatment that also had an amniocentesis at about 20 weeks RESULTS: Each subject had amniocentesis performed. Maternal-fetal transmission before amniocentesis occurred in only one of the 40 cases (2.5%, [95% CI:0 - 13.2%]). At delivery, two additional subjects had late gestation transmission. Considering all three cases with maternal-fetal transmission, the transmission rate was 7.5% of 40 cases, [95% CI: 1,6 - 20.4%]). All infected neonates were asymptomatic at birth. Matched historical controls were 108 pregnancies with 38 transmissions (35.2%, [95% CI: 26.2 - 45.0%]), which was significantly higher than in the HIG administration group. CONCLUSION After a primary maternal CMV infection in the first trimester, HIG administration prevents maternal-fetal transmission up to 20 weeks of gestation. This article is protected by copyright. All rights reserved.}, keywords = {}, pubstate = {published}, tppubtype = {article} } OBJECTIVE To examine the efficacy of biweekly hyperimmunoglobulin (HIG) administration to women with first trimester CMV infection for preventing maternal-fetal transmission of CMV. METHODS Subjects were 40 pregnant women with a primary CMV infection with a median gestational age at diagnosis of 9.6 weeks with a range of 5.1 to 14.3 weeks' gestation. On average, HIG administration started at 11.1 weeks and continued until 16.6 weeks' gestation. Within this interval, HIG was administered between 2 and 6 times. While CMV IgG monitoring showed periodic fluctuations during biweekly HIG administration cycles, high CMV IgG avidity indices remained stable over the whole treatment period. The results were compared with a historic cohort with first trimester CMV infection without treatment that also had an amniocentesis at about 20 weeks RESULTS: Each subject had amniocentesis performed. Maternal-fetal transmission before amniocentesis occurred in only one of the 40 cases (2.5%, [95% CI:0 - 13.2%]). At delivery, two additional subjects had late gestation transmission. Considering all three cases with maternal-fetal transmission, the transmission rate was 7.5% of 40 cases, [95% CI: 1,6 - 20.4%]). All infected neonates were asymptomatic at birth. Matched historical controls were 108 pregnancies with 38 transmissions (35.2%, [95% CI: 26.2 - 45.0%]), which was significantly higher than in the HIG administration group. CONCLUSION After a primary maternal CMV infection in the first trimester, HIG administration prevents maternal-fetal transmission up to 20 weeks of gestation. This article is protected by copyright. All rights reserved. |
Böttcher, S; Diedrich, S; Keeren, K Increased detection of enterovirus A71 infections, Germany, 2019 Artikel Eurosurveillance, 24 (39), S. 30005, 2019. @article{Bottcher.2019, title = {Increased detection of enterovirus A71 infections, Germany, 2019}, author = {S B\"{o}ttcher and S Diedrich and K Keeren}, doi = {10.2807/1560-7917.ES.2019.24.39.1900556}, year = {2019}, date = {2019-01-01}, journal = {Eurosurveillance}, volume = {24}, number = {39}, pages = {30005}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Exler, S; Daiminger, A; Grothe, M; Schalasta, G; Enders, G; Enders, M Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 117 , S. 33–36, 2019, ISSN: 1386-6532. @article{Exler.2019, title = {Primary cytomegalovirus (CMV) infection in pregnancy: Diagnostic value of CMV PCR in saliva compared to urine at birth}, author = {S Exler and A Daiminger and M Grothe and G Schalasta and G Enders and M Enders}, doi = {10.1016/j.jcv.2019.05.015}, issn = {1386-6532}, year = {2019}, date = {2019-01-01}, journal = {Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology}, volume = {117}, pages = {33--36}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Enders, M Zytomegalie, Ringelröteln und Co. - Pränatale Virus-Infektionen Artikel Gynäkologie + Geburtshilfe, 24 (3), S. 28–34, 2019, ISSN: 1439-3557. @article{Enders.2019, title = {Zytomegalie, Ringelr\"{o}teln und Co. - Pr\"{a}natale Virus-Infektionen}, author = {M Enders}, doi = {10.1007/s15013-019-1729-6}, issn = {1439-3557}, year = {2019}, date = {2019-01-01}, journal = {Gyn\"{a}kologie + Geburtshilfe}, volume = {24}, number = {3}, pages = {28--34}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Eggers, M Correction to: Infectious Disease Management and Control with Povidone Iodine Artikel Infectious diseases and therapy, 2019, ISSN: 2193-8229. @article{Eggers.2019b, title = {Correction to: Infectious Disease Management and Control with Povidone Iodine}, author = {M Eggers}, doi = {10.1007/s40121-019-00263-8}, issn = {2193-8229}, year = {2019}, date = {2019-01-01}, journal = {Infectious diseases and therapy}, abstract = {In the original publication, Figure~1 was incorrectly published. The correct figure is given here.}, keywords = {}, pubstate = {published}, tppubtype = {article} } In the original publication, Figure~1 was incorrectly published. The correct figure is given here. |
Eggers, M Infectious Disease Management and Control with Povidone Iodine Artikel Infectious diseases and therapy, 2019, ISSN: 2193-8229. @article{Eggers.2019, title = {Infectious Disease Management and Control with Povidone Iodine}, author = {M Eggers}, doi = {10.1007/s40121-019-00260-x}, issn = {2193-8229}, year = {2019}, date = {2019-01-01}, journal = {Infectious diseases and therapy}, abstract = {With reports of vancomycin-resistant enterococci recently emerging in hospital settings, renewed focus is turning to the importance of multifaceted infection prevention efforts. Careful compliance with established hygiene practices by healthcare workers together with effective antiseptic options is essential for the protection of patients from infectious agents. For over 60~years, povidone iodine (PVP-I) formulations have been shown to limit the impact and spread of infectious diseases with potent antiviral, antibacterial and antifungal effects. In addition to a lack of reported resistance, the benefits of PVP-I include an excellent safety profile and a broad spectrum of effect due to its multimodal action. Studies have shown that hand washing with PVP-I-based antiseptics is effective for the decontamination of skin, while PVP-I mouthwashes and gargles significantly reduce viral load in the oral cavity and the oropharynx. The importance of PVP-I has been emphasised by its inclusion in the World Health Organization's list of essential medicines, and high potency for virucidal activity has been observed against viruses of significant global concern, including hepatitis A and influenza, as well as the Middle-East Respiratory Syndrome and Sudden Acute Respiratory Syndrome coronaviruses. Together with its diverse applications in antimicrobial control, broad accessibility across the globe, and outstanding safety and tolerability profile, PVP-I offers an affordable, potent, and widely available antiseptic option.Funding Mundipharma Singapore Holding Pte Limited.}, keywords = {}, pubstate = {published}, tppubtype = {article} } With reports of vancomycin-resistant enterococci recently emerging in hospital settings, renewed focus is turning to the importance of multifaceted infection prevention efforts. Careful compliance with established hygiene practices by healthcare workers together with effective antiseptic options is essential for the protection of patients from infectious agents. For over 60~years, povidone iodine (PVP-I) formulations have been shown to limit the impact and spread of infectious diseases with potent antiviral, antibacterial and antifungal effects. In addition to a lack of reported resistance, the benefits of PVP-I include an excellent safety profile and a broad spectrum of effect due to its multimodal action. Studies have shown that hand washing with PVP-I-based antiseptics is effective for the decontamination of skin, while PVP-I mouthwashes and gargles significantly reduce viral load in the oral cavity and the oropharynx. The importance of PVP-I has been emphasised by its inclusion in the World Health Organization's list of essential medicines, and high potency for virucidal activity has been observed against viruses of significant global concern, including hepatitis A and influenza, as well as the Middle-East Respiratory Syndrome and Sudden Acute Respiratory Syndrome coronaviruses. Together with its diverse applications in antimicrobial control, broad accessibility across the globe, and outstanding safety and tolerability profile, PVP-I offers an affordable, potent, and widely available antiseptic option.Funding Mundipharma Singapore Holding Pte Limited. |
Kagan, K O; Maier, V; Sonek, J; Abele, H; Lüthgens, K; Schmid, M; Wagner, P; Hoopmann, M Fetal diagnosis and therapy, 45 (5), S. 317–324, 2019, ISSN: 1015-3837. @article{Kagan.2019, title = {False-Positive Rate in First-Trimester Screening Based on Ultrasound and Cell-Free DNA versus First-Trimester Combined Screening with Additional Ultrasound Markers}, author = {K O Kagan and V Maier and J Sonek and H Abele and K L\"{u}thgens and M Schmid and P Wagner and M Hoopmann}, doi = {10.1159/000489121}, issn = {1015-3837}, year = {2019}, date = {2019-01-01}, journal = {Fetal diagnosis and therapy}, volume = {45}, number = {5}, pages = {317--324}, abstract = {OBJECTIVE To determine whether screening for trisomy 21 based on first-trimester combined screening (FTCS) with assessment of nasal bone (NB), tricuspid flow (TCF), and ductus venosus flow (DVF) results in similar false-positive rates compared to ultrasound and cell-free DNA (cfDNA) screening. METHODS This is a subanalysis of a prospective randomized controlled trial which was performed between October 2015 and December 2016. Pregnant women with a normal first-trimester ultrasound examination at 11 to 13 weeks' gestation were randomized into two groups: (1) FTCS with assessment of the NB, TCF, and DVF (extended FTCS [eFTCS]), and (2) ultrasound + cfDNA screening. The false-positive rate in screening for trisomy 21 was defined as the primary outcome parameter. RESULTS The study population consisted of 688 women in each study arm. In the eFTCS group, the median delta fetal nuchal translucency thickness (NT) was 0.0 mm, free beta-hCG and PAPP-A were 0.96 and 1.11 MoM, and NB, TCF, and DVF PIV were abnormal in 0.9, 0.6, and 7.0% cases. In the ultrasound + cfDNA group, the median delta NT was 0.0 mm. In 10 pregnancies the cfDNA analysis was uninformative and the risk of trisomy 21 was based on eFTCS. There were no false-positive cases in the ultrasound + cfDNA group, whereas the false-positive rates were between 0.9 and 2.2% with eFTCS. CONCLUSION Screening for trisomy 21 based on ultrasound + cfDNA has a lower false-positive rate than screening based on eFTCS.}, keywords = {}, pubstate = {published}, tppubtype = {article} } OBJECTIVE To determine whether screening for trisomy 21 based on first-trimester combined screening (FTCS) with assessment of nasal bone (NB), tricuspid flow (TCF), and ductus venosus flow (DVF) results in similar false-positive rates compared to ultrasound and cell-free DNA (cfDNA) screening. METHODS This is a subanalysis of a prospective randomized controlled trial which was performed between October 2015 and December 2016. Pregnant women with a normal first-trimester ultrasound examination at 11 to 13 weeks' gestation were randomized into two groups: (1) FTCS with assessment of the NB, TCF, and DVF (extended FTCS [eFTCS]), and (2) ultrasound + cfDNA screening. The false-positive rate in screening for trisomy 21 was defined as the primary outcome parameter. RESULTS The study population consisted of 688 women in each study arm. In the eFTCS group, the median delta fetal nuchal translucency thickness (NT) was 0.0 mm, free beta-hCG and PAPP-A were 0.96 and 1.11 MoM, and NB, TCF, and DVF PIV were abnormal in 0.9, 0.6, and 7.0% cases. In the ultrasound + cfDNA group, the median delta NT was 0.0 mm. In 10 pregnancies the cfDNA analysis was uninformative and the risk of trisomy 21 was based on eFTCS. There were no false-positive cases in the ultrasound + cfDNA group, whereas the false-positive rates were between 0.9 and 2.2% with eFTCS. CONCLUSION Screening for trisomy 21 based on ultrasound + cfDNA has a lower false-positive rate than screening based on eFTCS. |
